April 19, 2024
Phase 1/2 Study Of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer
Select an appointment date and time from available spots listed below.